Small Financial Incentives to Promote Smoking Cessation
NCT ID: NCT02737566
Last Updated: 2024-07-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
320 participants
INTERVENTIONAL
2017-01-30
2022-02-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Incentives for Oklahoma Tobacco Helpline Engagement in Persistent Poverty Counties
NCT05095779
Financial Incentives for Smoking Cessation Treatment Engagement
NCT04601870
Patient Navigation and Financial Incentives to Promote Smoking Cessation
NCT02351609
Financial Incentives for Smoking Cessation
NCT00128375
Developing a Scalable Tobacco Cessation Program for Cancer Survivors and Caregivers
NCT06851936
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Description of Standard Care. According to the Clinical Practice Guideline, currently recommended components of an intensive tobacco treatment intervention include 1) initial assessment of willingness to participate, 2) the use of multiple types of clinicians (e.g., medical, non-medical), 3) at least 4 treatment sessions, in an individual- or group-counseling format, that are greater than 10 minutes in duration, 4) counseling that includes problem-solving, skills training, and social support components, and 5) and the opportunity to use effective medications to aid in tobacco cessation (e.g., nicotine patch, varenicline). The clinic currently offers all components of standard care. Specifically, individuals who would like to quit smoking are referred (typically via electronic medical record). Patients are scheduled for their initial appointment with a Tobacco Treatment Specialist for an individual counseling session and to discuss pharmacological treatment options. Nicotine replacement therapy is provided during the session, or other medications are prescribed via communication with the patient's physician or by a provider on-site. Those enrolled in the current study will be encouraged to attend at least 5 weekly group sessions to facilitate follow-up and the delivery of study incentives.
Visit 1, Part 1 (Recruitment/Screening). Individuals attending the initial clinic intake session will be provided with a 1-page informational handout with information about the study. After the session, study staff will check in with potential participants regarding their interest. Study staff will review the consent form with interested participants, and they will be screened for eligibility on-site in a private room in the clinic. Participant eligibility for the current study will not influence eligibility for standard treatment through the clinic. The Rapid Estimate of Adult Literacy in Medicine (REALM; see Appendix A) will be administered to ensure that all participants are able to read at ≥ sixth grade level (i.e., required to complete EMA and self-report questionnaires). Expired carbon monoxide (CO) will be measured with a Vitalograph BreathCO carbon monoxide monitor. Participants will be questioned about their 1) insurance status 2) age, 3) current level of smoking, 4) willingness to quit smoking, and 5) willingness/ability to attend 6 weekly sessions (including the first visit). Eligible participants may complete the assessment portion of visit 1.
Visit 1, Part 2 (Pre-Quit Assessment). Participants will complete self-report questionnaires on a laptop computer; and expired CO, weight, and height will be measured in a private room to ensure confidentiality. Participants will be provided with an Android smartphone and instructed regarding the use of the phone (participants may make personal calls) as well as the EMA procedures. Participants will receive 4 random prompts and 1 daily diary prompt (in the morning) during the normal waking hours each day for four consecutive weeks. Participants will be instructed to quit smoking at bedtime or 10:00 pm (whichever occurs first), on the evening prior to their next scheduled counseling session (one week later). Participants will be randomized to Standard Care (SC) or CM using a random numbers table and advised of their group assignment at the conclusion of visit 1. The appropriate schedule of payments (SC or CM) will be discussed with all participants (see Table 1). Visit 1 takes approximately 1 hour to complete, and participants will be scheduled to return for visit 2.
Visit 2 (Quit Day). Participants will complete self-report questionnaires on a laptop computer; and expired CO and weight will be measured in a private room to ensure confidentiality. Visit 2 takes approximately 40 minutes to complete. Participants randomized to the CM treatment will receive an additional payment if they self-report abstinence from smoking since 10 p.m. the prior evening, and their expired is CO level is \< 10 ppm (please note that the less stringent cut-off of 10 ppm will be used to verify abstinence at the first visit only, due to the recency of quitting). Participants who do not attend will be contacted by phone to obtain their self-reported smoking status only.
Visit 3 (1 Week Post-Quit). Participants will complete self-report questionnaires on a laptop computer; and expired carbon monoxide (CO) and weight will be measured in a private room to ensure confidentiality. Visit 3 takes approximately 30 minutes to complete. Participants randomized to the CM treatment will receive an additional payment if they self-report continuous abstinence from smoking since the quit day and have an expired CO level of ≤ 6 ppm. Participants who do not attend will be contacted by phone to obtain their self-reported smoking status.
Visit 4 (2 Weeks Post-Quit). Expired carbon monoxide (CO) and weight will be measured in a private room to ensure confidentiality. The visit 4 assessment takes approximately 5 minutes to complete. Participants randomized to the CM treatment will receive payment if they self-report continuous abstinence from smoking since the quit date and have an expired CO level of ≤ 6 ppm. Participants who do not attend will be contacted by phone to obtain their self-reported smoking status.
Visit 5 (3 Weeks Post-Quit). Expired carbon monoxide (CO) and weight will be measured in a private room to ensure confidentiality. The visit 5 assessment will take approximately 5 minutes to complete. Participants randomized to the CM treatment will receive payment if they self-report continuous abstinence from smoking since the quit date and have an expired CO level of ≤ 6 ppm. Participants who do not attend will be contacted by phone to obtain their self-reported smoking status.
Visit 6 (4 Weeks Post-Quit). Participants will complete self-report questionnaires on a laptop computer; and expired CO and weight will be measured in a private room to ensure confidentiality. The visit 6 assessment will take approximately 50 minutes to complete. Upon return of the smartphones, participants will be compensated based on the percentage of completed random assessments. Participants who do not attend will be contacted by phone and/or mail to request that the phone be returned by mail (postage paid envelopes will be sent) or in-person at the next visit. When participants return the phone they will be compensated according to the compensation schedule described above. Participants randomized to the CM treatment will receive an additional payment if they self-report continuous abstinence from smoking since the quit date and have an expired CO level of ≤ 6 ppm. Participants who do not attend will be contacted by phone to obtain their self-reported smoking status.
Visit 7 (8 Weeks Post-Quit). Participants will complete self-report questionnaires on a laptop computer; and expired CO and weight will be measured in a private room to ensure confidentiality. Participants will receive a payment for completion of the in-person assessments, which will take approximately 30 minutes to complete. Participants randomized to the CM treatment will receive an additional payment if they self-report abstinence from smoking over the past 7 days and have an expired CO level of ≤ 6 ppm. Participants who do not attend will be contacted by phone to obtain their self-reported smoking status.
Visit 8 (12 Weeks Post-Quit). Participants will complete self-report questionnaires on a laptop computer; and expired CO and weight will be measured in a private room to ensure confidentiality. Participants will receive a payment for completion of the in-person assessments, which will take approximately 30 minutes to complete. Participants randomized to the CM treatment will receive an additional payment if they self-report abstinence from smoking over the past 7 days and have an expired CO level of ≤ 6 ppm. Participants who do not attend will be contacted by phone to obtain their self-reported smoking status.
Visit 9 (26 Weeks Post-Quit Follow-Up). Participants will complete self-report questionnaires on a laptop computer; and expired CO and weight will be measured in a private room to ensure confidentiality. Participants will receive a payment for completion of the in-person assessments, which will take approximately 40 minutes to complete. Saliva cotinine will also be measured via NicAlert test strips to provide additional evidence of abstinence. Participants who do not attend will be contacted by phone to obtain their self-reported smoking status.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard Care + Financial Incentives
Participants randomized to Standard Care + Financial Incentives for Abstinence will be offered smoking cessation counseling and pharmacotherapy (standard care) and they will have the opportunity to earn small gift cards for biochemically-verified abstinence through 12 weeks post-quit. The amount of the gift cards will escalate each week from the quit date through 4 weeks post-quit with continuous abstinence. Participants who are non-abstinent at any visit may earn incentives for abstinence at the next visit, but the amount will reset to the starting level. Participants may additionally earn an additional gift card for abstinence at the 8 and 12 weeks post-quit visits.
Standard Care + Financial Incentives
Tobacco cessation counseling plus pharmacotherapy and financial incentives for quitting.
Standard Care
Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
Standard Care
Tobacco cessation counseling plus pharmacotherapy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard Care + Financial Incentives
Tobacco cessation counseling plus pharmacotherapy and financial incentives for quitting.
Standard Care
Tobacco cessation counseling plus pharmacotherapy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. earn a score ≥ 4 on the REALM indicating \> 6th grade English literacy level
3. are willing to quit smoking 7 days from their first visit
4. are ≥ 18 years of age
5. have an expired CO level ≥ 8 ppm suggestive of current smoking
6. are currently smoking ≥ 5 cigarettes per day
7. are willing and able to attend 9 study visits.
Exclusion Criteria
2. have already quit smoking
3. earn a score \<4 on the REALM indicating \< 7th grade literacy level
4. produce an expired CO level \< 8 ppm
5. are currently smoking \< 5 cigarettes per day
6. are unwilling or unable to attend study visits
7. are \< 18 years of age
8. are not uninsured or receiving Medicaid benefits
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
University of Oklahoma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Darla E. Kendzor, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Oklahoma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
TSET Health Promotion Research Center
Oklahoma City, Oklahoma, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Liang M, Koslovsky MD, Hebert ET, Kendzor DE, Businelle MS, Vannucci M. Bayesian continuous-time hidden Markov models with covariate selection for intensive longitudinal data with measurement error. Psychol Methods. 2023 Aug;28(4):880-894. doi: 10.1037/met0000433. Epub 2021 Dec 20.
Kendzor DE, Businelle MS, Frank-Pearce SG, Waring JJC, Chen S, Hebert ET, Swartz MD, Alexander AC, Sifat MS, Boozary LK, Wetter DW. Financial Incentives for Smoking Cessation Among Socioeconomically Disadvantaged Adults: A Randomized Clinical Trial. JAMA Netw Open. 2024 Jul 1;7(7):e2418821. doi: 10.1001/jamanetworkopen.2024.18821.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6260
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.